Emerald Advisers LLC Sells 76,472 Shares of KalVista Pharmaceuticals, Inc. $KALV

Emerald Advisers LLC lessened its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,264,023 shares of the specialty pharmaceutical company’s stock after selling 76,472 shares during the quarter. Emerald Advisers LLC owned 2.47% of KalVista Pharmaceuticals worth $25,445,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of KalVista Pharmaceuticals by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after acquiring an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new position in KalVista Pharmaceuticals in the 3rd quarter worth $24,360,000. State Street Corp boosted its stake in KalVista Pharmaceuticals by 21.3% in the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after purchasing an additional 336,195 shares during the period. Vestal Point Capital LP increased its holdings in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after purchasing an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC increased its holdings in KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after purchasing an additional 1,055,940 shares in the last quarter.

Analyst Upgrades and Downgrades

KALV has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Citizens Jmp lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 30th. Wall Street Zen upgraded KalVista Pharmaceuticals to a “hold” rating in a research note on Saturday, June 13th. Finally, JonesTrading downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $33.25.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $27.00 on Tuesday. The company’s 50-day moving average price is $26.90 and its two-hundred day moving average price is $20.54. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $27.00. The stock has a market capitalization of $1.44 billion, a PE ratio of -7.80 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $40.86 million during the quarter, compared to analysts’ expectations of $39.03 million. On average, equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 1,489 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $26.78, for a total value of $39,875.42. Following the completion of the sale, the chief financial officer owned 21,661 shares in the company, valued at $580,081.58. The trade was a 6.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Benjamin L. Palleiko sold 10,926 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $292,598.28. Following the completion of the sale, the chief executive officer directly owned 479,989 shares of the company’s stock, valued at $12,854,105.42. This represents a 2.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 39,971 shares of company stock valued at $965,493. 4.30% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.